PMA device
Bond Oracle HER2 Ihc System
Leica Biosystems · System, Test, Her-2/Neu, Ihc (MVC, Class III) · First FDA decision Apr 18, 2012, newest Feb 11, 2014Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "Bond Oracle HER2"
MAUDE reports
4
Brand "Bond Oracle HER2", since 2015
PubMed studies
0
Mentioning "Bond Oracle HER2"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Bond Oracle HER2 Ihc System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- BOND ORACLE HER2 IHC SYSTEMPMA supplement
P090015-S001 · Decided Feb 11, 2014 · 200 days after receipt · Normal 180 Day Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Bond Oracle HER2", any status and sponsor, newest update first.
No registered device study names "Bond Oracle HER2".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Bond Oracle HER2", and for the whole product code for context.
This brand
4 reports: 1 malfunction, 3 injury, 0 death
Whole product code MVC
12 reports: 4 malfunction, 5 injury, 0 death
Newest reports for this brand
LEICA BIOSYSTEMS NEWSCASTLE LTD
3004859032-2016-00003 · Received Feb 10, 2016 · Event dated Sep 14, 2015
Device type: System, Test, Her-2/Neu, Ihc (MVC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Misdiagnosis
3 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Bond Oracle HER2"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MVC.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2026
- HerceptestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Hercep TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2012
- PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2025
- Hercap TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Pathway Her 2 (Clone CB11)Ventana Medical Systems, Inc. · PMA 2002
- Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.